Published in Healthcare Mergers, Acquisitions and Ventures Week, March 17th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Ceragenix Pharmaceuticals.
Report 1: Ceragenix Pharmaceuticals, Inc. (CGXP), a biopharmaceutical company focused on infectious disease and dermatology, reported it has enrolled the 90th patient for a clinical study that compares the efficacy of the company's EpiCeram to Cutivate (a mid strength topical steroid) in patients with moderate to severe atopic dermatitis (eczema).
The multicenter study consists of 90 children between the ages of 6 months and 18...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.